*Stenotrophomonas maltophilia* is a glucose-nonfermenting, gram-negative bacillus that has emerged as a serious opportunistic pathogen, particularly among critically ill and immunocompromised patients \[[@CIT0001], [@CIT0002]\]. Though historically identified as a cause of nosocomial infections, community-onset infections increasingly are being reported \[[@CIT0003]\]. From 1996 to 2016, *S. maltophilia* was commonly isolated from patients hospitalized with pneumonia and bloodstream infection (BSI) \[[@CIT0004]\], and the incidence of *S. maltophilia* infection is increasing \[[@CIT0004]\].

*S. maltophilia* is intrinsically resistant to most currently available broad-spectrum antibiotics, including carbapenems and beta-lactams \[[@CIT0007]\]. This intrinsic resistance is due to the presence of chromosomally expressed beta-lactamases, L1 (a metallo-carbapenemase), and L2 (an extended-spectrum beta-lactamases), which together can hydrolyze nearly all beta-lactam antibiotics including carbapenems. In vitro activity is observed with tetracyclines and fluoroquinolones, but resistance can be rapidly induced mainly due to efflux pumps \[[@CIT0004], [@CIT0010]\]. Trimethoprim/sulfamethoxazole (TMP-SMX) generally is considered the treatment of choice for *S. maltophilia* infection, although consideration of *S. maltophilia* in treatment guidelines is sparse \[[@CIT0005], [@CIT0011], [@CIT0012]\]. Additionally, a recent study suggests that *S. maltophilia* susceptibility to TMP-SMX may be decreasing globally, due in part to acquired antibiotic resistence \[[@CIT0004], [@CIT0010]\]. Fluoroquinolones may be alternatives for TMP-SMX treatment in *S. maltophilia* infections due to their comparable effects on mortality \[[@CIT0013]\].

Because *S. maltophilia* is intrinsically resistant to most antibiotics, it is not included in antimicrobial resistance surveillance studies because only the acquired resistance meets the consensus definition of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria \[[@CIT0014]\]. Only a limited number of antibiotics are considered for in vitro susceptibility testing of *S. maltophilia* \[[@CIT0017]\].

Assessing the pathogenicity of *S. maltophilia* is difficult. Clinical isolates from the respiratory tract sources are often mixed with other pathogenic bacteria, and distinguishing colonization from a true infection caused by *S. maltophilia* is problematic \[[@CIT0018]\]. Much of the observational clinical reports of *S. maltophilia* infections have focused on bloodstream infections (BSIs) where convincing evidence of pathogenicity can be determined \[[@CIT0019]\].

Despite rising global incidence and patterns of resistance among *S. maltophilia* BSIs, no broad, population-based studies of *S. maltophilia* in the United States have been conducted. Such information is necessary to understand associated risk factors, antibiotic treatment patterns, and outcomes of *S. maltophilia* BSIs. The purpose of this study was to identify patient characteristics, microbiology susceptibility, and treatment decisions for patients with *S. maltophilia* BSI in a large, geographically diverse sample of US hospitals.

METHODS {#s1}
=======

Study Design and Data Source {#s2}
----------------------------

A retrospective analysis of characteristics and outcomes in patients with *S. maltophilia*--positive blood cultures was conducted using the Premier Healthcare Database (PHD; Premier Inc., Charlotte, NC, USA) \[[@CIT0020]\]. PHD is a large, US-based, service-level, all-payer database that contains administrative, health care utilization, and financial data from patient encounters for \>231 million unique patients sourced from \>1000 contributing hospital/healthcare systems \[[@CIT0020]\]. Hospitals included in PHD cover a range of geographically diverse facilities, including a mix of academic, community, and large hospital systems, representing \~25% of annual US inpatient admissions \[[@CIT0020]\]. Patient hospital encounters, including diagnosis and procedures, are coded using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) classification system \[[@CIT0020]\].

This study sourced data from a subset of the PHD that includes 181 hospitals with microbiology laboratory data such as specimen source, pathogen identification, and antibiotic susceptibility test results. Patient, hospital, and microbiology characteristics, antibiotic treatments, infection-associated lengths of stay, and discharge status were assessed.

Study Population {#s3}
----------------

Unique non--cystic fibrosis adult (≥18 years of age) inpatients with positive blood cultures for any gram-negative pathogen from October 2, 2010, to September 30, 2015, were included in this analysis. Specific focus was placed on patients with *S. maltophilia* BSI. If patients had multiple admissions with a positive blood culture for *S. maltophilia*, the first record was used as the index culture, and the remainder were excluded from analysis. The draw date of the first positive blood culture for *S. maltophilia* is considered the index date, and results in this analysis are based on index cultures.

Measures and Outcomes {#s4}
---------------------

### Subject Demographics {#s5}

The demographics of patients with *S. maltophilia* BSI, including age at the time of hospital admission, race, sex, admitting ICD-9 diagnosis codes, primary ICD-9 diagnosis codes at discharge, Charlson comorbidity Index (CCI) score and categories based on ICD-9 diagnoses codes, and source of admission were captured in this analysis.

### Microbiology Characteristics {#s6}

Each BSI was classified as hospital-acquired, health care--associated, or community-onset, using previously published definitions \[[@CIT0021], [@CIT0022]\]. Infections with an index date \>3 days after admission were classified as hospital-acquired infections. Infections with an index date of ≤3 days following admission and evidence of recent contact with a health care setting (such as having transferred from health care facilities or having had a hospitalization in the same hospital within the last 30 days) were classified as health care--associated infections. Infections with an index date that was ≤3 days after hospital admission with no evidence of previous contact with a health care setting were classified as community-onset.

In vitro susceptibility testing of *S. maltophilia* isolates to carbapenems is not recommended due to intrinsic resistance, and therefore all *S. maltophilia* isolates were a priori defined as carbapenem-resistant (CR) \[[@CIT0017]\].

### Antibiotic Treatments {#s7}

Based on the presumed availability of identification and susceptibility testing of the positive blood isolate, antibiotic use was divided into 3 time periods: before index date, empiric treatment (index date + 3 days), and definitive treatment (≥4 days post--index date). These treatment periods were used as a proxy for clinical decision-making regarding the choice of antibiotic therapy and antibiotic stewardship. The empiric treatment, often utilizing broad-spectrum antimicrobial agents, represents the initial antibiotic therapy to cover multiple possible pathogens. Once physicians have knowledge of the identified pathogen, definitive treatment may be more pathogen-targeted.

TMP-SMX, fluoroquinolones (levofloxacin or ciprofloxacin), doxycycline, ceftazidime, and minocycline were considered appropriate antibiotics because they are included in Clinical and Laboratory Standards Institute (CLSI) susceptibility testing for *S. maltophilia* or they have high in vitro activity against *S. maltophilia*. Use of these products in empiric and definitive treatment periods was tabulated to assess the proportion of patients likely receiving appropriate treatment.

### Infection Course {#s8}

The infection course was characterized by 3 components: (1) classification of infection onset (community-onset, health care--associated, or hospital-acquired), (2) infection-associated length of stay (LOS), and (3) discharge status. Infection-associated LOS was defined as the number of days between the index date and discharge date. Discharge status included in-hospital mortality, discharge to home or hospice, or transfer to another health care facility (eg, skilled nursing facility, long-term acute care hospital).

Statistical Analysis {#s9}
--------------------

Descriptive analyses summarizing the study population, antibiotic use, and infection course including discharge status were performed using SAS, version 9.4 (SAS Institute, Cary, NC, USA). Continuous variables were summarized using mean, median, and range. Categorical variables were summarized as frequencies and percentages.

RESULTS {#s10}
=======

Subject Demographics and Hospital Characteristics {#s11}
-------------------------------------------------

From October 2010 to September 2015, a total of 52 285 inpatient blood culture samples from 46 381 patients tested positive for gram-negative pathogens, and 1602 (3.06%) of the patients were CR. Among all patients with CR gram-negative BSIs, *S. maltophilia* was the most common (n = 486), followed by *Pseudomonas aeruginosa* (n = 379), *Klebsiella pneumoniae* (n = 253), and *Acinetobacter baumannii* (n = 235) ([Figure 1](#F1){ref-type="fig"}).

![Carbapenem-resistant (CR), gram-negative pathogens causing bacteremia in the United States, based on the 1602 patients identified. The most common CR pathogens were *Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii,* and *Proteus mirabilis.*](ofaa141f0001){#F1}

The mean age at admission for *S. maltophilia* BSI patients (SD) was 57.2 (17.0) years. Most patients were white (67.1%), with 19.1% black, and about half were female (52.2%). Over 77% of patients came from home before hospital admission, and 10.5% of patients were transferred from another health care facility ([Table 1](#T1){ref-type="table"}; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The most common diagnosis at admission was an unspecified fever (12.3%); upon discharge, the most common diagnosis was BSI due to venous catheter (14.4%) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Nearly 89% were from urban hospitals, and 86.0% were in hospitals with ≥200 beds.

###### 

Patient Characteristics

  Characteristic                                   No.           \%
  ------------------------------------------------ ------------- ------
  Age at index, y                                                
   Mean (SD)                                       52.2 (17.0)   
   Median (min--max)                               53 (18--89)   
  Gender                                                         
   Male                                            233           47.9
  Race                                                           
   White                                           326           67.1
   Black                                           93            19.1
   Hispanic                                        2             0.4
   Other                                           64            13.2
   Unknown                                         1             0.2
  Source of admission                                            
   Ambulatory                                      409           84.2
   Transferred from another health care facility   51            10.5
   Unknown                                         26            5.3
  Classification of infection                                    
   Community-onset infection                       217           44.6
   Health care--associated infection               32            6.6
   Hospital-acquired infection                     237           48.8
  Charlson comorbidity index                                     
  ** **Mean (SD)                                   3.05 (2.59)   
  ** **Median (min--max)                           3 (0--13)     

Abbreviation: BSI, bloodstream infection.

Microbiology Characteristics and Timing of Infection {#s12}
----------------------------------------------------

Nearly 45% (n = 217) of *S. maltophilia* BSIs were assessed as community-onset, meaning that the index date was within 3 days of admission without previously identified health care--related contact ([Table 1](#T1){ref-type="table"}), and 161 (74.2%) community-onset infections were present upon admission (day 0 or 1). An additional 6.6% (n = 32) of patients were assessed as health care--associated infections, meaning that the index date was within 3 days of admission among those transferred from another health care facility or who had a prior hospitalization at the same hospital within the last 30 days. Less than half (n = 237, 48.8%) were considered to have a hospital-acquired infection. In most patients (n = 443, 91.2%), the original source of the *S. maltophilia* BSI was not identified, with the remainder (n = 43, 8.8%) having prior or concomitant *S. maltophilia* respiratory infection.

Pathogen isolates were tested for antimicrobial susceptibility following the CLSI M100 guidelines \[[@CIT0023]\]. In this sample, *S. maltophilia* isolates were most frequently tested for susceptibility to TMP-SMX and fluoroquinolones (95% and 83% of tested isolates, respectively). For isolates tested for TMP-SMX, 95% were susceptible, and in those tested for fluoroquinolone (either ciprofloxacin or levofloxacin), 84% were susceptible ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Although tetracycline, including minocycline and tigecycline, was tested for susceptibility in only 15% of cultures, 91.8% of isolates were found to be susceptible. The antibiotic agents with the lowest rates of susceptibility were penicillin/beta-lactamase inhibitors (42%) and third-generation cephalosporin (44%). Additional therapies may have been tested but unreported.

Antibiotic Treatment Patterns {#s13}
-----------------------------

Antibiotic utilization over the study period is described in [Table 2](#T2){ref-type="table"}. The rate of oral or parenteral antibiotics prescribed is described for 2 different periods: in the empiric period of treatment and in the definitive period of treatment. Only treatments with activity against gram-negative pathogens are included in this report. In the empiric period, piperacillin/tazobactam was the most commonly used (32.3%), followed by cefepime (24.7%) and levofloxacin (19.3%) ([Table 2](#T2){ref-type="table"}). In the definitive period, levofloxacin (48.9%) and/or TMP-SMX (38.3%) were most commonly used. Patients receiving appropriate treatment (ie, any use of a fluoroquinolone, ceftazidime, doxycycline, minocycline, or TMP-SMX) increased from 39.1% during the empiric period to 85.8% in the definitive period ([Table 2](#T2){ref-type="table"}). Interestingly, a large percentage of patients continued to receive a carbapenem in the definitive period (5.0%--14.0%).

###### 

Gram-Negative Treatment Administration by Percentage of Patients Across 2 Time Intervals: Empiric Treatment (Index Culture + 3 Days) and Definitive Treatment (≥4 Days Post--Index Culture)

                                                                                                                                                                           Empiric Use (n = 486)   Definitive Use (n = 444^a^)                   
  ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ----------------------- ----------------------------- ------- ------- -------
  Fluoroquinolone                                                                                                                                Levofloxacin              19.3                    48.9                          **↑**           
                                                                                                                                                 Ciprofloxacin             8.02                    14.2                          **↑**           
                                                                                                                                                 Moxifloxacin              1.4                     2.0                                   **-**   
  Cephalosporin                                                                                                                                  Cefepime                  24.7                    19.8                                          **↓**
                                                                                                                                                 Ceftriaxone               14.4                    9.5                                           **↓**
                                                                                                                                                 Cefazolin                 3.9                     7.7                           **↑**           
                                                                                                                                                 Ceftazidime               4.9                     10.8                          **↑**           
                                                                                                                                                 Other cephalosporins      1.7                     1.6                                   \-      
  Penicillin/beta-lactamase inhibitor                                                                                                            Piperacillin/tazobactam   32.3                    27.0                                          **↓**
                                                                                                                                                 Ampicillin/sulbactam      2.3                     2.5                                   \-      
                                                                                                                                                 Ticarcillin/clavulanate   0.6                     2.5                           **↑**           
                                                                                                                                                 Amoxicillin/clavulanate   0.2                     0.7                                   \-      
  Carbapenem                                                                                                                                     Meropenem                 15.0                    14.0                                          **↓**
                                                                                                                                                 Ertapenem                 5.4                     6.3                                   \-      
                                                                                                                                                 Imipenem                  7.2                     6.5                                   \-      
                                                                                                                                                 Doripenem                 4.9                     5.0                                   \-      
  Folic acid inhibitor/sulfonamide                                                                                                               TMP-SMX                   10.5                    38.3                          **↑**           
  Aminoglycoside                                                                                                                                 Gentamicin                9.3                     7.0                                           **↓**
                                                                                                                                                 Tobramycin                7.4                     5.6                                           **↓**
                                                                                                                                                 Amikacin                  1.0                     2.0                           **↑**           
  Tetracycline                                                                                                                                   Tigecycline               2.9                     5.4                           **↑**           
                                                                                                                                                 Doxycycline               2.3                     2.9                                   \-      
                                                                                                                                                 Minocycline               0.4                     1.6                           **↑**           
                                                                                                                                                 Demeclocycline            0.2                     0.7                                   \-      
                                                                                                                                                 Tetracycline              0.0                     0.2                                   \-      
  Monobactam                                                                                                                                     Aztreonam                 3.5                     3.8                                   \-      
  \% of patients who received at least 1 of appropriate treatments^c^ (any fluoroquinolone, TMP-SMX, doxycycline, ceftazidime, or minocycline)                             39.1                    85.8                          **↑**           

Patients may have been managed by multiple drug classes and multiple drugs within each class during the hospitalization. The percentages here reflect the percentage of patients who ever used any anti-infective. For initiation of gram-negative treatments in the empiric and definitive periods, refer to Supplementary Table 4.

Abbreviation: TMP-SMX, trimethoprim-sulfamethoxazole.

^a^Forty-two patients were lost to follow-up between the empiric and definitive phases of treatment: 19 died during the empiric period, and 23 were discharged during the empiric period.

^b^Directional arrows for changes are limited to changes of \>1%. All other changes are considered within margins of error.

^c^Appropriate treatments are defined as the drugs included in CLSI susceptibility testing for *S. maltophilia*.

Infection Course (Onset, LOS, and Outcome) {#s14}
------------------------------------------

Nearly 45% of patients had positive culture within 3 days of admission without documentation of prior health care association, which we defined as community-onset. The median infection-associated LOS was 9 days, with an average (SD) of 13.2 (19.8) days. Upon discharge, most *S. maltophilia* patients (60.9%) were discharged to home. Approximately one-fourth (24.1%) of patients were discharged to another health care facility, and a small percentage of them (2.3%) were discharged to hospice. In this data set, 12.8% of *S. maltophilia* BSI patients died before discharge ([Table 3](#T3){ref-type="table"}).

###### 

Onset, LOS, and Discharge Status, by Carbapenem-Resistant Pathogen

                                                                  Carbapenem-Resistant Pathogens^a^                                             
  --------------------------------------------------------------- ----------------------------------- ------------- ------------- ------------- -----------
  Classification of infection, %                                                                                                                
   Community-onset infection                                      44.6                                0             0.5           0.4           0
   Health care--associated infection                              6.6                                 40.4          42.5          44.3          73.9
   Hospital-acquired infection                                    48.8                                59.6          57.0          55.3          26.1
  Infection-associated length of stay, d                                                                                                        
   No.                                                            486                                 235           379           253           115
   Mean (SD)                                                      13.2 (19.8)                         12.9 (16.3)   16.3 (22.6)   15.0 (20.7)   9.9 (8.9)
   Median (min--max)                                              9 (0--353)                          9 (1--143)    10 (1--197)   10 (1--187)   7 (2--50)
  Discharge status, %                                                                                                                           
   No.                                                            486                                 235           379           253           115
   Discharge to home                                              60.9                                7.7           23.2          15.8          26.1
   Discharge to hospice                                           2.3                                 2.1           6.3           10.7          6.1
   Discharge to other facilities (eg, skilled nursing facility)   24.1                                47.7          46.2          53.0          60.9
   In-hospital mortality                                          12.8                                47.7          24.3          20.6          7.0

Abbreviation: LOS, length of stay.

^a^Pathogens were considered carbapenem-resistant if the interpretation for any carbapenem was listed as resistant or intermediate, excluding ertapenem for *A. baumannii* and *P. aeruginosa*.

The comparison with other CR gram-negative BSIs showed some substantial differences. Patients with *S. maltophilia* BSI had a much higher rate of community-onset than observed in the other 4 most common CR pathogens (range, 0%--0.5%), although their median infection-related LOS were similar. Crude in-hospital mortality was lower for patients with *S. maltophilia* BSI compared with patients with CR *A. baumannii,* CR *P. aeruginosa,* and CR *K. pneumoniae* BSIs (42.6%, 24.3%, and 20.6%, respectively) ([Table 3](#T3){ref-type="table"}).

DISCUSSION {#s15}
==========

In this large, retrospective, multicenter cohort study of *S. maltophilia* BSI patients in the United States, we found that *S. maltophilia* is the most common cause of CR gram-negative BSI in the United States, with \>40% of the infections identified as community-onset (44.6%). Because *S. maltophilia* is not included in most surveillance studies for antimicrobial resistance, this is an important epidemiologic fact for physicians considering empiric treatment in septic patients. A recent report identifying difficult-to-treat resistant (DTR) gram-negative bacteremia utilizing the same Premier database failed to include *S. maltophilia* as a contributing pathogen because *S. maltophilia* did not meet the consensus definitions of MDR and XDR \[[@CIT0024], [@CIT0025]\].

This study identified 486 unique patients with *S. maltophilia* BSI. The majority of the patients were \>50 years old, white, and female. Diagnoses at admission were often nonspecific, whereas on discharge diagnoses were more frequently related to medical device--associated bacteremia, including venous catheter (14.4%) and vascular devices (6.6%). A previously published, single-center patient chart review study in Greece found that catheter-related *S. maltophilia* BSIs were approximately one-third (36.4%) of *S. maltophilia* BSIs, a much higher percentage than found in our study \[[@CIT0026]\]. The difference might relate to fact that a catheter-related infection may be more thoroughly identified in a chart review than when using reported diagnosis codes in a secondary electronic health care database such as the PHD.

This study found that most isolates of *S. maltophilia* were susceptible to TMP-SMX (94.6%) and tetracycline (92%). More interestingly, despite these high susceptibility rates, TMP-SMX in oral or parenteral form was only used in 38.3% of patients during the definitive treatment period. Other studies have found similar susceptibility rates for TMP-SMX, ranging from 86.8% to 97.1% \[[@CIT0026]\]. Samonis et al. in their 2012 publication found that most isolates were susceptible or intermediately susceptible to TMP-SMX (86.8%), yet \<10% of patients (9.1%) received it at any time and only 5.5% of patients received it as empirical therapy \[[@CIT0026]\]. Similarly, our study found relatively low usage of TMP-SMX, especially during empiric treatment (10.5%), although a higher percentage of patients (38.3%) received this treatment during the definitive treatment period. This demonstrates that TMP-SMX is not often included in empiric regimens for patients with suspected gram-negative sepsis, even when there is concern for carbapenem resistance. Furthermore, fluoroquinolones such as levofloxacin and ciprofloxacin were more likely to be used than TMP-SMX even after *S. maltophilia* had been definitively identified from blood culture. This is consistent with the conclusions of Ko et al. that levofloxacin may be an alternative to TMP-SMX \[[@CIT0013]\]. When considering all appropriate treatments for *S. maltophilia* BSI, only 39.1% received 1 of these treatments during the empiric period. This suggests that *S. maltophilia* is not often considered a likely cause of BSI. It was not until blood culture results identified the pathogen and susceptibility that 85.8% of patients received a treatment appropriate for *S. maltophilia*.

In this patient population, the average infection-associated LOS with *S. maltophilia* (SD) was 13.2 (19.8) days, similar to patients with BSIs from other CR gram-negative pathogens. In contrast to LOS, crude mortality in these patients did not appear to be as high as BSIs from other CR pathogens such as *A. baumannii, P. aeruginosa,* or *K. pneumoniae*.

This study has several strengths and limitations. This study utilized a large data set representative of US hospitals to identify patient characteristics and the burden of *S. maltophilia* BSI. It is the first study to identify the importance of *S. maltophilia* as the most common CR gram-negative bacterial pathogen causing bacteremia in the United States. Although the geographic regional prevalence may differ, *S. maltophilia* is a cause of BSI across the United States in a variety of hospital settings. In addition, the available microbiology data allow for proxy assessment of temporal patterns between timing of culture relative to hospital admission and initiation or adjustment of antibiotic treatment. It should be noted, however, that while PHD is largely representative of US hospitals, the southern portion of the United States is overrepresented in the database \[[@CIT0020]\]. This may have an impact on the generalizability of our results to the entire US population, as physicians prescribing antibiotics vary from state to state, with southern states showing increased prescription trends \[[@CIT0030]\]. A further limitation is that the PHD does not capture medical history and medical treatment before hospitalization, which could impact the characterization of health care--associated infections. Our figure of 6.6% representing health care--associated infection is likely an underestimate of health care--associated admissions due to limitations in reporting health care--related activities before admission. Consistent with the previous literature, the source of gram-negative BSI is often not identified, although many BSIs appear to be device related.

CONCLUSIONS {#s16}
===========

In this representative multicenter US study, *S. maltophilia* was found to be the most common cause of carbapenem-resistant gram-negative bacteremia, over half of which were present upon admission, representing community onset. Ironically, *S. maltophilia* is not included in most surveillance studies for antimicrobial resistance. This study demonstrated that patients at risk for *S. maltophilia* BSI are highly variable and that empiric treatment for possible CR gram-negative BSI does not include appropriate antibiotics. Standard of treatment is not clearly defined, and only a third of patients receive the recommended treatment with TMP-SMX during the definitive treatment period. Further efforts are needed to adequately describe patients with *S. maltophilia* infections in hospital settings across the United States to more adequately characterize treatment decisions in real-world practice and the resulting effectiveness.

Supplementary Data {#s17}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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